Enara Bio
- Biotech or pharma, therapeutic R&D
Enara Bio is leading the development of Dark Antigen® immunotherapies by interrogating both sides of the immune synapse - the interface of recognition between cancer cells and T cells.
From the tumor cell side, we look beyond the known proteome into the genomic dark matter to identify and characterize Dark Antigens that are uniquely presented on the surface of cancer cells, shared across broad patient populations, and homogenously expressed within tumors.
On the T cell side, we are discovering and characterizing T-cell receptors (TCRs) that induce potent anti-tumor responses against our Dark Antigen targets and other emerging targets of interest.
These discoveries are fueling a pipeline of solid tumor T cell engagers designed to improve treatment outcomes for broad patient populations.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}